Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.63 |
| ▸ | DRD3 | P35462 | 8/20 | 0.63 |
| ▸ | DRD2 | P14416 | 5/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL230363 | 0.88 | DRD2 (0.62) | HTR2ADRD3DRD2 | |
| SCHEMBL229413 | 0.87 | HTR2A (0.58) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL229382 | 0.87 | HTR2A (0.62) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL229383 | 0.87 | HTR2A (0.62) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL229412 | 0.87 | HTR2A (0.58) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL2533090 | 0.86 | SMN1; SMN2 (0.55) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL227504 | 0.86 | SMN1; SMN2 (0.55) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL228757 | 0.86 | DRD2 (0.57) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL2533668 | 0.86 | DRD2 (0.57) | HTR2ADRD3DRD2HTR2CHTR7 | |
| SCHEMBL229244 | 0.85 | DRD2 (0.60) | HTR2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | claimed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | HTR2A 1/4885DRD3 18/4885DRD2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.